Key result
Remifentanil during neonatal non-cardiac surgery is associated with zero intractable adverse events or postoperative apnea.
Why the study?
Remifentanil has favorable pharmacologic characteristics for pediatric anesthesia, but its application to neonatal anesthesia has not been validated yet.
Is remifentanil feasible and safe for general anesthesia in neonates undergoing non-cardiac surgery?
Population
68 neonates undergoing non-cardiac surgery under general anesthesia in Japan
Comparison
Neonates receiving remifentanil infusion during anesthesia vs no remifentanil
Design
14-month retrospective case series at a tertiary care pediatric hospital
Authors
Loading...
May support remifentanil in neonatal anesthesia; hypothesis-generating and should not yet change practice.
Observational (n=68)
No
Is remifentanil feasible and safe for general anesthesia in neonates undergoing non-cardiac surgery?
Remifentanil appears feasible and safe for use in general anesthesia for neonates undergoing non-cardiac surgery.
Soontrakom et al. (2018) conducted an observational in Neonates undergoing non-cardiac surgery (n=68). Remifentanil was evaluated on Intractable adverse events including postoperative apnea. Remifentanil use during general anesthesia for neonatal non-cardiac surgery was feasible and associated with no intractable adverse events or postoperative apnea.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: